Literature DB >> 15742661

Vaccination in the control of bluetongue in endemic regions: the South African experience.

B Dungu1, C Potgieter, B Von Teichman, T Smit.   

Abstract

The eradication of bluetongue virus (BTV) from endemic regions of Africa is virtually impossible due to the role played by the widely distributed Culicoides spp. of midge vectors and the ubiquitous distribution of reservoir species. In endemic areas attempts can only be made to limit the occurrence of bluetongue (BT) disease and its economic impact through vaccination. Despite several potential problems (teratogenicity, risk of reassortment and reversion to virulence of the attenuated viral strains), epidemiological and recent molecular data support the fact that the live attenuated vaccine that has been used for decades in enzootic regions, provides a safe and efficacious means to control the disease in regions of southern Africa, as well as other areas of the world.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15742661

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  9 in total

1.  Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains.

Authors:  Sushila Maan; Narender S Maan; Piet A van Rijn; René G P van Gennip; Anna Sanders; Isabel M Wright; Carrie Batten; Bernd Hoffmann; Michael Eschbaumer; Chris A L Oura; Abraham C Potgieter; Kyriaki Nomikou; Peter P C Mertens
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

2.  Determinants of bluetongue virus virulence in murine models of disease.

Authors:  Marco Caporale; Rachael Wash; Attilio Pini; Giovanni Savini; Paola Franchi; Matthew Golder; Janet Patterson-Kane; Peter Mertens; Luigina Di Gialleonardo; Gisella Armillotta; Rossella Lelli; Paul Kellam; Massimo Palmarini
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

Review 3.  Bluetongue: a historical and epidemiological perspective with the emphasis on South Africa.

Authors:  Peter Coetzee; Maria Stokstad; Estelle H Venter; Mette Myrmel; Moritz Van Vuuren
Journal:  Virol J       Date:  2012-09-13       Impact factor: 4.099

4.  Transient Bluetongue virus serotype 8 capsid protein expression in Nicotiana benthamiana.

Authors:  Albertha R van Zyl; Ann E Meyers; Edward P Rybicki
Journal:  Biotechnol Rep (Amst)       Date:  2015-12-07

5.  Evolution and phylogenetic analysis of full-length VP3 genes of Eastern Mediterranean bluetongue virus isolates.

Authors:  Kyriaki Nomikou; Chrysostomos I Dovas; Sushila Maan; Simon J Anthony; Alan R Samuel; Maria Papanastassopoulou; Narender S Maan; Olga Mangana; Peter P C Mertens
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

6.  Novel virostatic agents against bluetongue virus.

Authors:  Linlin Gu; Volodymyr Musiienko; Zhijun Bai; Aijian Qin; Stewart W Schneller; Qianjun Li
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

7.  A protective bivalent vaccine against Rift Valley fever and bluetongue.

Authors:  Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Julio Benavides; Aitor Nogales; Rafael Blasco; Alejandro Brun; Javier Ortego
Journal:  NPJ Vaccines       Date:  2020-07-30       Impact factor: 7.344

8.  Bluetongue virus outer-capsid protein VP2 expressed in Nicotiana benthamiana raises neutralising antibodies and a protective immune response in IFNAR -/- mice.

Authors:  Petra C Fay; Houssam Attoui; Carrie Batten; Fauziah Mohd Jaafar; George P Lomonossoff; Janet M Daly; Peter P C Mertens
Journal:  Vaccine X       Date:  2019-06-22

Review 9.  A review of experimental infections with bluetongue virus in the mammalian host.

Authors:  Peter Coetzee; Moritz van Vuuren; Estelle H Venter; Maria Stokstad
Journal:  Virus Res       Date:  2014-01-24       Impact factor: 3.303

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.